Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation - Scorecard - MDSpire

Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

  • By

  • Paola Facheris

  • Francesco Piscazzi

  • Giovanni Fiorillo

  • Mario Valenti

  • Antonio Costanzo

  • Riccardo G. Borroni

  • April 24, 2026

  • 0 min

Share

Clinical Scorecard: Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

At a Glance

CategoryDetail
Condition
Key MechanismsTargeting the IL-23/IL-17 axis with IL-23p19 inhibitors, emphasizing their role in improving patient outcomes.
Target Population
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • A
      • d
      • d
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • i
      • n
      • g
      • p
      • a
      • r
      • a
      • m
      • e
      • t
      • e
      • r
      • s
      • a
      • n
      • d
      • r
      • i
      • s
      • k
      • s
      • a
      • s
      • s
      • o
      • c
      • i
      • a
      • t
      • e
      • d
      • w
      • i
      • t
      • h
      • t
      • r
      • e
      • a
      • t
      • m
      • e
      • n
      • t
      • .

      Risks

        Patient & Prescribing Data

        Verify and update the dosing schedule as per the latest guidelines.

        Clinical Best Practices

        • additional_practice

        References

        Original Source(s)

        Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

        • by Paola Facheris, Francesco Piscazzi, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, Riccardo G. Borroni

        • April 24, 2026

        Related Content

        Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice

        IL-17, IL-23 Therapies Lead Psoriasis Care

        Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

        Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada